Taxus Cardium Pharmaceuticals Group, Inc. is regenerative therapeutics company. The company focuses on the late-stage clinical and development of regenerative medicine therapeutics. Its product candidates include Generx, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of cardiac microvascular insufficiency due to increasing coronary artery disease, and Excellagen, an acellular biological skin substitute designed as a wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. The company was founded by Christopher J. Reinhard and Tyler M. Dylan-Hyde in December 2003 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is the 52-week high for Taxus Cardium Pharmaceuticals Group Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Taxus Cardium Pharmaceuticals Group Inc 52 week high is $0.0001 as of May 10, 2024.
What is the 52-week low for Taxus Cardium Pharmaceuticals Group Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Taxus Cardium Pharmaceuticals Group Inc 52 week low is $0.00 as of May 10, 2024.
What is the 50-day moving average of Taxus Cardium Pharmaceuticals Group Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Taxus Cardium Pharmaceuticals Group Inc 50-day moving average is $0.00.